Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma

Highly sensitive reporter-gene assays have been developed that allow both the direct vascular endothelial growth factor (VEGF) neutralizing activity of bevacizumab and the ability of bevacizumab to activate antibody dependent cellular cytotoxicity (ADCC) to be quantified rapidly and in a highly spec...

Descripción completa

Detalles Bibliográficos
Autores principales: Lallemand, Christophe, Ferrando-Miguel, Rosa, Auer, Michael, Iglseder, Sarah, Czech, Theresa, Gaber-Wagener, Anouk, Di Pauli, Franziska, Deisenhammer, Florian, Tovey, Michael G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593583/
https://www.ncbi.nlm.nih.gov/pubmed/33178180
http://dx.doi.org/10.3389/fimmu.2020.515556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593583/
https://www.ncbi.nlm.nih.gov/pubmed/33178180
http://dx.doi.org/10.3389/fimmu.2020.515556

Ejemplares similares